CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia

M. Dal Bo; P. Bulian; R. Bomben; A. Zucchetto; Francesca Maria Rossi; Federico Pozzo; Erika Tissino; Dania Benedetti; Tamara Bittolo; P. Nanni; I. Cattarossi; E. Zaina; H. Chivilò; M. Degan; F. Zaja; G. Pozzato; A. Chiarenza; F. Di Raimondo; M. I. Del Principe; G. Del Poeta; D. Rossi; G. Gaidano; V. Gattei

doi:10.1038/leu.2016.88

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia

M. Dal Bo, P. Bulian, R. Bomben, A. Zucchetto, Francesca Maria Rossi, Federico Pozzo, Erika Tissino, Dania Benedetti, Tamara Bittolo, P. Nanni, I. Cattarossi, E. Zaina, H. Chivilò, M. Degan, F. Zaja, G. Pozzato, A. Chiarenza, F. Di Raimondo, M. I. Del Principe, G. Del PoetaD. Rossi, G. Gaidano, V. Gattei

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

CD49d, the alpha-chain of the integrin heterodimer α4β1, was identified among the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia (CLL), along with IGHV mutational status and deletion of the 17p chromosome involving TP53. In addition to TP53, the clinical relevance of NOTCH1, SF3B1 and BIRC3 gene mutations has been recently emphasized. By analyzing a cohort of 778 unselected CLL patients, we assessed the clinical relevance of CD49d as an OS predictor in subgroups defined by mutation/deletion of the TP53, NOTCH1, SF3B1 and BIRC3 genes. In this context, CD49d emerged as an independent predictor of OS in multivariate Cox analysis (Hazard ratio =1.88, P

Original language	English
Pages (from-to)	2011
Number of pages	2018
Journal	Leukemia
DOIs	https://doi.org/10.1038/leu.2016.88
Publication status	Published - May 20 2016

ASJC Scopus subject areas

Hematology
Cancer Research
Anesthesiology and Pain Medicine

Access to Document

10.1038/leu.2016.88

Cite this

Dal Bo, M., Bulian, P., Bomben, R., Zucchetto, A., Rossi, F. M., Pozzo, F., Tissino, E., Benedetti, D., Bittolo, T., Nanni, P., Cattarossi, I., Zaina, E., Chivilò, H., Degan, M., Zaja, F., Pozzato, G., Chiarenza, A., Di Raimondo, F., Del Principe, M. I., ... Gattei, V. (2016). CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia, 2011. https://doi.org/10.1038/leu.2016.88

Dal Bo, M , Bulian, P , Bomben, R, Zucchetto, A, Rossi, FM , Pozzo, F , Tissino, E, Benedetti, D, Bittolo, T, Nanni, P, Cattarossi, I, Zaina, E, Chivilò, H, Degan, M, Zaja, F, Pozzato, G, Chiarenza, A, Di Raimondo, F, Del Principe, MI, Del Poeta, G, Rossi, D, Gaidano, G & Gattei, V 2016, 'CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia', Leukemia, pp. 2011. https://doi.org/10.1038/leu.2016.88

@article{6ad54550ec1f4114bc83d059d2d5f549,

title = "CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia",

abstract = "CD49d, the alpha-chain of the integrin heterodimer α4β1, was identified among the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia (CLL), along with IGHV mutational status and deletion of the 17p chromosome involving TP53. In addition to TP53, the clinical relevance of NOTCH1, SF3B1 and BIRC3 gene mutations has been recently emphasized. By analyzing a cohort of 778 unselected CLL patients, we assessed the clinical relevance of CD49d as an OS predictor in subgroups defined by mutation/deletion of the TP53, NOTCH1, SF3B1 and BIRC3 genes. In this context, CD49d emerged as an independent predictor of OS in multivariate Cox analysis (Hazard ratio =1.88, P",

author = "{Dal Bo}, M. and P. Bulian and R. Bomben and A. Zucchetto and Rossi, {Francesca Maria} and Federico Pozzo and Erika Tissino and Dania Benedetti and Tamara Bittolo and P. Nanni and I. Cattarossi and E. Zaina and H. Chivil{\`o} and M. Degan and F. Zaja and G. Pozzato and A. Chiarenza and {Di Raimondo}, F. and {Del Principe}, {M. I.} and {Del Poeta}, G. and D. Rossi and G. Gaidano and V. Gattei",

year = "2016",

month = may,

day = "20",

doi = "10.1038/leu.2016.88",

language = "English",

pages = "2011",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia

AU - Dal Bo, M.

AU - Bulian, P.

AU - Bomben, R.

AU - Zucchetto, A.

AU - Rossi, Francesca Maria

AU - Pozzo, Federico

AU - Tissino, Erika

AU - Benedetti, Dania

AU - Bittolo, Tamara

AU - Nanni, P.

AU - Cattarossi, I.

AU - Zaina, E.

AU - Chivilò, H.

AU - Degan, M.

AU - Zaja, F.

AU - Pozzato, G.

AU - Chiarenza, A.

AU - Di Raimondo, F.

AU - Del Principe, M. I.

AU - Del Poeta, G.

AU - Rossi, D.

AU - Gaidano, G.

AU - Gattei, V.

PY - 2016/5/20

Y1 - 2016/5/20

N2 - CD49d, the alpha-chain of the integrin heterodimer α4β1, was identified among the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia (CLL), along with IGHV mutational status and deletion of the 17p chromosome involving TP53. In addition to TP53, the clinical relevance of NOTCH1, SF3B1 and BIRC3 gene mutations has been recently emphasized. By analyzing a cohort of 778 unselected CLL patients, we assessed the clinical relevance of CD49d as an OS predictor in subgroups defined by mutation/deletion of the TP53, NOTCH1, SF3B1 and BIRC3 genes. In this context, CD49d emerged as an independent predictor of OS in multivariate Cox analysis (Hazard ratio =1.88, P

AB - CD49d, the alpha-chain of the integrin heterodimer α4β1, was identified among the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia (CLL), along with IGHV mutational status and deletion of the 17p chromosome involving TP53. In addition to TP53, the clinical relevance of NOTCH1, SF3B1 and BIRC3 gene mutations has been recently emphasized. By analyzing a cohort of 778 unselected CLL patients, we assessed the clinical relevance of CD49d as an OS predictor in subgroups defined by mutation/deletion of the TP53, NOTCH1, SF3B1 and BIRC3 genes. In this context, CD49d emerged as an independent predictor of OS in multivariate Cox analysis (Hazard ratio =1.88, P

UR - http://www.scopus.com/inward/record.url?scp=84969638928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969638928&partnerID=8YFLogxK

U2 - 10.1038/leu.2016.88

DO - 10.1038/leu.2016.88

M3 - Article

SN - 0887-6924

SP - 2011

JO - Leukemia

JF - Leukemia

ER -

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this